Experience

• 

  Ergomed clinical research

  Apr 2009 - Dec 2013

  • Clinical Operation Lead/ Clinical Research Trainer

    May 2012 - Dec 2013

  • Senior Clinical Research Associate

    Apr 2009 - Apr 2012
• 

  Ever neuro pharma

  Dec 2013 - Aug 2015

  Market access manager

  Monitored and analyzed on publicly available information and MoH, Government, State Duma, FAS, MoIT, Roszdravnadzor, media insights on reimbursement trends and emerging changes in public healthcare policy and strategically support the business in Russia Developed a decision-making process scheme in respect to possible reimbursement segments, pointing out key stakeholders and their roles in decision-making process thus reinforcing company effectiveness Developed and maintained strong relationships with the Chief non-staff MoH specialists ensuring Cerebrolysin listings at the federal levelPrepared and submitted EDL, ONLS, Trade Names listing dossiers on Cerebrolysyn for the Federal MoH thus securing the federal status quoPromoted and supported Cerebrolysin listing in TPGG (regional l’gota), and hospital formularies in cooperation with the company field force teams via preparation of justified dossiers and/or letters to regional MoHs and HC facilities clientsDeveloped company Key accounts and KOLs through execution of innovative programs in TBI, stroke and anesthesiology treatment (e.g. Sklif, MONIKI, Vserosiysky center of emergency and radiation medicine n.a. A. M. Nikiforov of EMERCOM)Provided ongoing «24/7/365» support by developed and implementation of trainings and respective materials on compliance, pharmacoeconomy, market access and reimbursement essentials for the field force team to secure state procurementsPromoted and realized pharmacoeconomical modeling study in acute stroke project as clinical and economical justification for state procurements Show less

• 

  Avva pharmaceuticals (mc develop)

  Aug 2016 - Feb 2017

  Head of medical department

  Overall administration, budgeting, launch and management of clinical trials in cardiology and gastroenterology (BEQ, IIb, III, IV phase, observational)

• 

  Boehringer ingelheim

  Feb 2017 - Jun 2022

  As a Market Access partner was resposible for cross-functional support to business (marketing, sales, legal, regulatory, commercial, financial depts). Developed Market Access strategies within the framework of the pre-launch of Praxbind, Jardiance and spesolimab.Co-developed the Federal Project "Fight with T2D" as a member of the working group with estimated budget as of 100 billion rubles in 2023-2025.Promoted inclusion of Jardiance into the List of drugs for the Federal Project "Fight against CVD" with funding of 10.15 billion rubles per year.Received a gratitude from the company's management for personal contribution to the inclusion of Metalyse, Jardiance, Pradaxa and Trajenta in the EDL and ONLS lists.Developed and implemented pricing strategies for Jardiance, Metalyse, Synjardi and Glixambi. Conducted registration, indexation and mandatory re-registration of the EDL prices, which allowed the company to achieve continuous circulation of products on the Russian market. Created a service of regional access promotion of drugs. As part of this work, build up a structure, developed and implemented numerous tools, manuals, conducted trainings, certifications for sales etc. Integrated practical HEOR into the company's business operations, which helped in promoting products in the budget channel.Innovative regional market access tools not only gained recognition at the local and international levels, but also contributed to the growth of sales in the budget channel (e.g. the increase in the share of Metalyse was 21% in 2018, the sales plan of Jardiance was exceeded by 131% in 2021). Show less

  • Market Access Lead

    Apr 2022 - Jun 2022

  • Senior Market Access Manager

    Apr 2019 - Jun 2022

  • Federal Market Access Manager

    Feb 2017 - Mar 2019
• 

  Moscow business school

  Jul 2022 - now

  Market access and clinical research trainer-consultant